Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder - Full Text View

Purpose

The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment.

Condition	Intervention	Phase
Depressive Disorder	Drug: Duloxetine Hydrochloride	Phase III

MedlinePlus related topics:

Depression

ChemIDplus related topics:

Duloxetine Duloxetine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder

Further study details as provided by Eli Lilly and Company:

Study Start Date:	May 2002
Estimated Study Completion Date:	July 2003

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Signed the informed consent
Meet criteria for major depressive disorder without psychotic features.
Have a level of understanding sufficient to provide informed consent and to communicate with the investigator and site personnel.
Have had at least one other major depressive episode prior to the one being experienced at study entry.
You are reliable and agree to keep all appointments for clinic visits, tests and procedures required by the protocol.

Exclusion Criteria:

You have had treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry.
Any women who are pregnant or breast feeding.
If you have any serious medical illnesses other than major depressive disorder.
If you have previously participated in a clinical trial for duloxetine.
Any previous or current diagnosis of bipolar, schizophrenia, or other psychotic disorders.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00036309

Locations


United States, North Carolina
	For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)
	Durham, North Carolina, United States

Sponsors and Collaborators

Eli Lilly and Company

More Information

Publications indexed to this study:

Hudson JI, Perahia DG, Gilaberte I, Wang F, Watkin JG, Detke MJ. Duloxetine in the treatment of major depressive disorder: an open-label study. BMC Psychiatry. 2007 Aug 28;7:43.

Study ID Numbers:	4445, F1J-MC-HMBC
First Received:	May 8, 2002
Last Updated:	July 18, 2006
ClinicalTrials.gov Identifier:	NCT00036309
Health Authority:	United States: Food and Drug Administration

Keywords provided by Eli Lilly and Company:

Major Depressive Disorder

Diagnostic and Statistical Manual of Mental Disorders Fourth Edition-defined major depressive disorder without psychotic features

Study placed in the following topic categories:

Dopamine

Depression

Mental Disorders

Mood Disorders

Psychotic Disorders

Depressive Disorder, Major

Depressive Disorder

Serotonin

Duloxetine

Behavioral Symptoms

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors

Neurotransmitter Uptake Inhibitors

Neurotransmitter Agents

Disease

Molecular Mechanisms of Pharmacological Action

Adrenergic Agents

Adrenergic Uptake Inhibitors

Physiological Effects of Drugs

Psychotropic Drugs

Serotonin Uptake Inhibitors

Pharmacologic Actions

Pathologic Processes

Serotonin Agents

Therapeutic Uses

Dopamine Agents

Central Nervous System Agents

Antidepressive Agents

ClinicalTrials.gov processed this record on October 10, 2008

Sponsored by:	Eli Lilly and Company
Information provided by:	Eli Lilly and Company
ClinicalTrials.gov Identifier:	NCT00036309